NAD+ and the Hallmarks of Aging

In 2013, Lopez-Otin and colleagues published a landmark paper in Cell that organized the biology of aging around nine “hallmarks” — cellular and molecular processes that collectively drive the aging phenotype. The framework has since been updated to include additional hallmarks, but the core set remains the most widely used map for understanding what actually happens inside cells as they age, and why organisms deteriorate over time. For anyone trying to understand why longevity supplements work — or should work — the hallmarks framework is the essential context.

NAD+ connects to this framework not at one point but at many. It is involved — directly or through the enzymes it activates — in at least six of the hallmarks of aging. That breadth is both what makes NAD+ so interesting as a longevity target and what makes vague claims about it (“NAD+ fights aging”) simultaneously true and uninformative. This article maps NAD+’s specific role in each relevant hallmark, explains the mechanistic connections, and distinguishes where the evidence is strong from where it is preliminary.

The Hallmarks Framework: A Brief Orientation

The hallmarks of aging, as originally described and subsequently updated, include: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis. Not all are equally relevant to NAD+, and not all are equally well-characterized as drivers versus consequences of aging. The framework is a map, not a complete mechanistic theory.

For the purposes of understanding NAD+’s position in aging biology, the most directly relevant hallmarks are: genomic instability, epigenetic alterations, mitochondrial dysfunction, cellular senescence, deregulated nutrient sensing, and chronic inflammation. NAD+ connects to each through specific enzymatic mechanisms rather than vague antioxidant or “cellular energy” effects. Understanding what those connections are — and how strong the evidence behind them is — is what this article is for.

A useful complement to this article is the foundational piece on how NAD+ levels change as you age, which covers why NAD+ declines in the first place — the upstream problem that makes these downstream hallmark connections relevant.

Hallmark 1: Genomic Instability — NAD+ and DNA Repair

Genomic instability — the accumulation of DNA damage over time — is considered a primary hallmark of aging and a driver of cancer, cellular senescence, and organ dysfunction. DNA is damaged thousands of times per cell per day by reactive oxygen species, environmental mutagens, replication errors, and normal metabolic byproducts. The fidelity of DNA repair systems determines how well this damage is corrected before it accumulates into mutations or structural chromosome abnormalities.

NAD+’s connection to genomic stability runs through two enzyme families: PARPs and SIRT1.

PARP enzymes (poly ADP-ribose polymerases) are among the first responders to DNA strand breaks. When DNA is damaged, PARP1 — the primary PARP isoform — is rapidly activated and consumes NAD+ to add chains of ADP-ribose to itself and other proteins at the damage site, recruiting repair machinery. This process is essential for efficient DNA repair. PARP1 can consume enormous amounts of NAD+ when activated — under conditions of heavy DNA damage, PARP activation can deplete cellular NAD+ by 80% or more within minutes. Chronic PARP activation from ongoing DNA damage therefore creates a competing demand on the NAD+ pool that can deprive other NAD+-dependent enzymes of their substrate.

SIRT1 and SIRT6 — NAD+-dependent deacetylases — also participate in DNA repair by deacetylating and thereby activating key repair proteins. SIRT6 in particular is required for efficient repair of double-strand breaks, the most dangerous form of DNA damage. Declining NAD+ with age therefore impairs sirtuin-mediated DNA repair at the same time that increasing oxidative stress with age is generating more damage to be repaired.

The result is a vicious cycle: more DNA damage → more PARP activation → more NAD+ consumption → less NAD+ available for sirtuins and other repair processes → less efficient repair → more damage accumulation. Restoring NAD+ levels through supplementation could theoretically interrupt this cycle by ensuring adequate substrate availability for both PARP and sirtuin-dependent repair. The detailed evidence on this specific mechanism is covered in the article on NAD+ and DNA repair.

Hallmark 2: Epigenetic Alterations — Sirtuins as Epigenetic Regulators

Epigenetic alterations — changes in DNA methylation patterns, histone modifications, and chromatin architecture that alter gene expression without changing the DNA sequence — accumulate with age in characteristic patterns that have become the basis for epigenetic clocks used to measure biological age. These alterations include both hypermethylation of some promoter regions and global hypomethylation, along with changes in histone acetylation that affect how tightly DNA is packaged and which genes are accessible for transcription.

Sirtuins are the primary NAD+-dependent regulators of histone acetylation. SIRT1, SIRT2, SIRT3, SIRT6, and SIRT7 are all histone deacetylases — enzymes that remove acetyl groups from histones, generally promoting chromatin compaction and gene silencing. As NAD+ declines with age, sirtuin activity declines, histone acetylation increases, and chromatin becomes less well-organized. This epigenetic drift — the progressive loss of proper gene regulation — is proposed as a central mechanism of aging by Sinclair and others, framed as the “information theory of aging.”

SIRT1’s role in maintaining epigenetic stability goes beyond histones: it also regulates the activity of DNMT3L, involved in DNA methylation maintenance, and interacts with other chromatin-modifying complexes. The epigenetic consequences of declining NAD+ and sirtuin activity therefore ramify across multiple levels of gene regulation simultaneously.

Whether restoring NAD+ meaningfully reverses age-related epigenetic alterations in humans is one of the most important open questions in longevity biology. Animal studies showing NAD+ repletion can partially restore epigenetic patterns in aged tissues are intriguing. Human evidence on epigenetic age reversal with NAD+ precursors is preliminary, and the methodology for measuring epigenetic age reliably enough to detect such changes is still developing. This question is examined in depth in the article on can you actually reverse biological age?

Hallmark 3: Mitochondrial Dysfunction — NAD+ at the Core of Energy Metabolism

Mitochondrial dysfunction is one of the most directly NAD+-connected hallmarks, and the mechanistic link here is the most straightforward in the set. NAD+ is the primary electron acceptor in the citric acid cycle and the substrate whose oxidized/reduced cycling drives the electron transport chain — the mitochondrial machinery that generates most of the cell’s ATP. Without adequate NAD+, the electron transport chain cannot function at full capacity, ATP production declines, and cells shift toward less efficient energy metabolism pathways.

Beyond its direct role as an electron carrier, NAD+ activates SIRT1 and SIRT3 — the mitochondrial sirtuin — which regulate mitochondrial biogenesis (production of new mitochondria) through PGC-1α deacetylation, and which maintain the quality of the existing mitochondrial pool through effects on mitophagy (selective elimination of damaged mitochondria). Declining NAD+ with age therefore impairs mitochondrial function through multiple simultaneous mechanisms: reduced electron transport chain efficiency, reduced biogenesis, and impaired quality control.

The human trial evidence for NMN and NR producing mitochondrial effects is among the stronger parts of the clinical literature. Elhassan et al. (2019) found increased skeletal muscle NAD+ and improved mitochondrial function markers in older men on NR. Remie et al. (2020) found increased muscle mitochondrial protein content with NR despite null metabolic endpoints. These findings confirm that NAD+ precursor supplementation reaches muscle tissue and produces mitochondrial effects — the clinical significance of which depends on whether those effects translate to functional outcomes in the populations studied.

The article on mitochondria and aging covers the full mechanistic and clinical picture of mitochondrial decline as a driver of aging.

Hallmark 4: Cellular Senescence — NAD+, PARP, and the SASP

Senescent cells — cells that have permanently exited the cell cycle but remain metabolically active — accumulate with age and secrete a pro-inflammatory cocktail of cytokines, proteases, and growth factors called the SASP (senescence-associated secretory phenotype). The SASP damages surrounding tissue, promotes chronic inflammation, and can push neighboring cells toward senescence, creating a spreading dysfunction. Senescence is covered in depth in the article on senescent cells and senolytics.

NAD+’s connection to senescence runs through several mechanisms. PARP1 activation is a driver of the DNA damage response that triggers cellular senescence — excessive PARP activation from unrepaired DNA damage can push cells into senescence rather than allowing repair and resumption of normal function. NAD+ depletion from chronic PARP activation may therefore accelerate senescence induction.

More directly, SIRT1 normally suppresses NF-κB — the master transcription factor for inflammatory gene expression and a key driver of the SASP. When NAD+ declines and SIRT1 activity falls, NF-κB suppression is reduced, SASP components are more actively expressed, and the inflammatory burden from senescent cells increases. Restoring NAD+ and SIRT1 activity may therefore reduce SASP expression in existing senescent cells even without clearing them — a meaningful anti-inflammatory effect distinct from the senolytic approach of eliminating senescent cells entirely.

CD38 — the enzyme that degrades NAD+ and is a primary driver of the age-related NAD+ decline — is significantly upregulated in senescent cells, creating a direct mechanistic link between senescent cell accumulation and NAD+ depletion. This is covered in detail in the article on the CD38 problem: why NAD+ gets depleted faster as you age.

Hallmark 5: Deregulated Nutrient Sensing — NAD+, AMPK, and mTOR

Nutrient sensing pathways — primarily the insulin/IGF-1 pathway, mTOR, and AMPK — regulate cellular responses to nutrient availability and are central to longevity across model organisms from yeast to mammals. The general finding from decades of research is that reducing nutrient signaling (through calorie restriction, rapamycin, or AMPK activation) extends healthy lifespan, while chronically elevated nutrient signaling (through overnutrition or sedentary lifestyle) accelerates aging.

NAD+ connects to this hallmark primarily through its relationship with AMPK and sirtuins. AMPK — the cellular energy sensor that activates when the AMP:ATP ratio rises — directly phosphorylates and activates SIRT1, creating a pathway by which nutrient scarcity (sensed by AMPK) feeds into sirtuin-mediated longevity gene expression. Conversely, SIRT1 deacetylates and activates LKB1, an upstream AMPK kinase, creating a positive feedback between the two longevity pathways. NAD+ sits at the center of this network as the substrate that makes sirtuin activity possible.

The mTOR connection is less direct: SIRT1 can suppress mTOR signaling through deacetylation of raptor, a component of the mTORC1 complex. To the extent that NAD+ declines reduce SIRT1 activity, mTOR may be less well-suppressed, promoting the anabolic, pro-aging signaling that mTOR hyperactivation drives. The full context of these pathway interactions is in the article on sirtuins, AMPK, and mTOR.

Hallmark 6: Chronic Inflammation — NAD+ and Inflammaging

Chronic low-grade inflammation — termed “inflammaging” — is both a hallmark of aging and a driver of most age-related diseases. It arises from multiple sources: accumulated senescent cells secreting SASP components, age-related changes in immune cell populations and function, increased gut permeability allowing bacterial products into circulation, and declining regulatory mechanisms that normally suppress inappropriate inflammation.

NAD+’s anti-inflammatory connections run through SIRT1’s suppression of NF-κB (described above), through SIRT2 and SIRT3 effects on NLRP3 inflammasome activation, and through CD38 — which is expressed in immune cells and upregulated during inflammatory responses, creating a direct mechanism by which inflammation depletes NAD+ and thereby removes the NAD+-dependent brakes on further inflammation. This inflammatory-NAD+ depletion cycle is one of the more important mechanistic links between aging biology and NAD+ supplementation rationale.

SIRT1 activation also suppresses the production of several pro-inflammatory cytokines directly, including TNF-alpha and IL-6, through mechanisms independent of NF-κB. The anti-inflammatory effects of NAD+ repletion are therefore multifaceted and consistent across multiple mechanistic pathways rather than dependent on a single route.

Where the Evidence Is Strong and Where It Is Preliminary

Being specific about evidence quality matters when a molecule connects to as many pathways as NAD+ does. The risk of the hallmarks framing is that it can make any compound with broad biological activity sound like a comprehensive aging solution — which overstates what is established and what remains speculative.

The evidence is strong that NAD+ is mechanistically involved in DNA repair, mitochondrial function, and the regulation of sirtuin-dependent processes in all the ways described above. These connections are established at the biochemical level through decades of research across multiple model organisms and in human cell systems.

The evidence is promising but preliminary that restoring NAD+ in aged humans produces meaningful improvements in these hallmark processes at a whole-organism level. The human trial evidence reviewed in the articles on NMN clinical trials and NR clinical trials shows functional effects in specific populations and contexts. Generalizing those findings to broad hallmark reversal in healthy adults requires more and larger trials than exist today.

The evidence is speculative that NMN or NR supplementation meaningfully slows aging in healthy humans over long time periods, extends lifespan, or reverses biological age in any robust general sense. These claims are consistent with the mechanistic picture but are not established by human clinical data.

Frequently Asked Questions

Does addressing NAD+ decline address all the hallmarks of aging at once?

No — and the framing of “addressing NAD+ addresses aging” reflects a mechanistic simplification that the evidence does not support. NAD+ connects meaningfully to six of the hallmarks, but the connections vary in strength and directness. More importantly, the hallmarks not connected to NAD+ — telomere attrition, loss of proteostasis, stem cell exhaustion, gut dysbiosis — are not addressed by NAD+ precursor supplementation. A comprehensive approach to longevity supplements addresses multiple mechanisms, not just NAD+ replenishment. The article on the advanced longevity stack outlines how to build a multi-mechanism protocol.

Is the hallmarks framework the consensus view among aging researchers?

The Lopez-Otin hallmarks framework is widely used and cited — it is the most influential organizing framework in aging biology — but it is not a settled consensus in the sense of being universally accepted as complete or mechanistically definitive. Different researchers emphasize different hallmarks as primary drivers versus secondary consequences, and ongoing debates exist about causal ordering. The framework is best understood as a useful map rather than a final theory. It has been explicitly updated since the 2013 original, with additional hallmarks added as evidence accumulated.

If NAD+ declines drive so many aging processes, why don’t we see more dramatic results from NMN and NR supplementation?

Several reasons. First, NAD+ decline is one of multiple concurrent changes driving aging — restoring NAD+ removes one constraint without addressing others. Second, the hallmark connections described here operate over long timescales; a 12-week trial is unlikely to produce dramatic reversal of processes that accumulated over decades. Third, the degree of NAD+ restoration achieved by oral supplementation — meaningful but not complete — may be sufficient to slow some hallmark progression without reversing it. Fourth, many of the most meaningful longevity outcomes simply cannot be measured in the timeframe of current trials. The honest expectation is that NAD+ precursor supplementation contributes to healthier aging as part of a broader approach, not that it produces dramatic measurable reversal of aging in any individual trial.